Literature DB >> 19152230

Power and sample size calculation for log-rank test with a time lag in treatment effect.

Daowen Zhang1, Hui Quan.   

Abstract

The log-rank test is the most powerful non-parametric test for detecting a proportional hazards alternative and thus is the most commonly used testing procedure for comparing time-to-event distributions between different treatments in clinical trials. When the log-rank test is used for the primary data analysis, the sample size calculation should also be based on the test to ensure the desired power for the study. In some clinical trials, the treatment effect may not manifest itself right after patients receive the treatment. Therefore, the proportional hazards assumption may not hold. Furthermore, patients may discontinue the study treatment prematurely and thus may have diluted treatment effect after treatment discontinuation. If a patient's treatment termination time is independent of his/her time-to-event of interest, the termination time can be treated as a censoring time in the final data analysis. Alternatively, we may keep collecting time-to-event data until study termination from those patients who discontinued the treatment and conduct an intent-to-treat analysis by including them in the original treatment groups. We derive formulas necessary to calculate the asymptotic power of the log-rank test under this non-proportional hazards alternative for the two data analysis strategies. Simulation studies indicate that the formulas provide accurate power for a variety of trial settings. A clinical trial example is used to illustrate the application of the proposed methods. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19152230      PMCID: PMC2692036          DOI: 10.1002/sim.3501

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  A comparison of sample size methods for the logrank statistic.

Authors:  E Lakatos; K K Lan
Journal:  Stat Med       Date:  1992-01-30       Impact factor: 2.373

2.  Sample size calculation for complex clinical trials with survival endpoints.

Authors:  J H Shih
Journal:  Control Clin Trials       Date:  1995-12

3.  Sample sizes based on the log-rank statistic in complex clinical trials.

Authors:  E Lakatos
Journal:  Biometrics       Date:  1988-03       Impact factor: 2.571

4.  Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint.

Authors:  D A Schoenfeld; J R Richter
Journal:  Biometrics       Date:  1982-03       Impact factor: 2.571

5.  Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification.

Authors:  J M Lachin; M A Foulkes
Journal:  Biometrics       Date:  1986-09       Impact factor: 2.571

  5 in total
  8 in total

1.  Design and analysis of clinical trials in the presence of delayed treatment effect.

Authors:  Tony Sit; Mengling Liu; Michael Shnaidman; Zhiliang Ying
Journal:  Stat Med       Date:  2016-02-02       Impact factor: 2.373

2.  Designing therapeutic cancer vaccine trials with delayed treatment effect.

Authors:  Zhenzhen Xu; Boguang Zhen; Yongsoek Park; Bin Zhu
Journal:  Stat Med       Date:  2016-11-02       Impact factor: 2.373

3.  Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials.

Authors:  Haesook Teresa Kim; Robert Gray
Journal:  Clin Trials       Date:  2012-02-21       Impact factor: 2.486

4.  Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.

Authors:  Lu Tian; Haoda Fu; Stephen J Ruberg; Hajime Uno; Lee-Jen Wei
Journal:  Biometrics       Date:  2017-09-12       Impact factor: 2.571

5.  Designing cancer immunotherapy trials with random treatment time-lag effect.

Authors:  Zhenzhen Xu; Yongsoek Park; Boguang Zhen; Bin Zhu
Journal:  Stat Med       Date:  2018-09-10       Impact factor: 2.373

6.  Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy.

Authors:  XiaoDong Guo; Lu Xiong; Lingxiang Yu; Ruisheng Li; ZhaoHai Wang; Bo Ren; JingHui Dong; Boan Li; Dadong Wang
Journal:  Diagn Pathol       Date:  2014-09-18       Impact factor: 2.644

7.  Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.

Authors:  Kim Jachno; Stephane Heritier; Rory Wolfe
Journal:  BMC Med Res Methodol       Date:  2019-05-16       Impact factor: 4.615

8.  SOX6 suppresses the development of lung adenocarcinoma by regulating expression of p53, p21CIPI , cyclin D1 and β-catenin.

Authors:  Liyan Lv; Min Zhou; Jian Zhang; Fang Liu; Li Qi; Shuai Zhang; Yi Bi; Yan Yu
Journal:  FEBS Open Bio       Date:  2019-12-12       Impact factor: 2.693

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.